Latest From CARsgen Therapeutics
Only two of seven applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical need to patients faster were successful last month.
Some of the most anticipated data at ASH are for therapies targeting BCMA in multiple myeloma, including a next-gen CAR-T from bluebird and Celgene as well as Amgen's novel BiTE, but an update from China's Legend Biotech and J&J could steal the show.
China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.
Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.
- Therapeutic Areas
- Parent & Subsidiaries
- CARsgen Therapeutics
- Senior Management
Zonghai Li, MD, PhD, CEO
HuaMao Wang, PhD, COO
HaiOu Chen, EVP, Fin.
Leigh Hsu, PhD, SVP, Bus. Dev,
- Contact Info
Phone: 21 64501828
388 Yindu Rd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.